Beijing Scitop Bio Tech Co Ltd (300858) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing Scitop Bio Tech Co Ltd (300858) has a cash flow conversion efficiency ratio of 0.024x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥44.72 Million ≈ $6.54 Million USD) by net assets (CN¥1.83 Billion ≈ $267.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Beijing Scitop Bio Tech Co Ltd to measure how much of total assets are equity-financed.
Beijing Scitop Bio Tech Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Beijing Scitop Bio Tech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Beijing Scitop Bio Tech Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Beijing Scitop Bio Tech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Scitop Bio Tech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jinxiandai Information Industry Co
SHE:300830
|
0.012x |
|
Hailir Pesticides and Chemicals Group Co Ltd
SHG:603639
|
0.047x |
|
Trilogy Metals Inc
TO:TMQ
|
-0.023x |
|
E&R Engineering
TWO:8027
|
0.062x |
|
Flexium Interconnect Inc
TW:6269
|
-0.005x |
|
Sage Therapeutics Inc
NASDAQ:SAGE
|
-0.159x |
|
Markor International Home Furnishings Co Ltd
SHG:600337
|
0.027x |
|
Satellogic V Inc
NASDAQ:SATL
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Beijing Scitop Bio Tech Co Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Beijing Scitop Bio Tech Co Ltd from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see 300858 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.84 Billion ≈ $269.66 Million |
CN¥123.44 Million ≈ $18.06 Million |
0.067x | -15.65% |
| 2024-12-31 | CN¥1.79 Billion ≈ $261.87 Million |
CN¥142.11 Million ≈ $20.80 Million |
0.079x | +28.30% |
| 2023-12-31 | CN¥1.73 Billion ≈ $253.59 Million |
CN¥107.27 Million ≈ $15.70 Million |
0.062x | -29.26% |
| 2022-12-31 | CN¥1.70 Billion ≈ $248.26 Million |
CN¥148.46 Million ≈ $21.72 Million |
0.088x | -23.23% |
| 2021-12-31 | CN¥967.40 Million ≈ $141.56 Million |
CN¥110.27 Million ≈ $16.14 Million |
0.114x | +59.44% |
| 2020-12-31 | CN¥932.59 Million ≈ $136.47 Million |
CN¥66.67 Million ≈ $9.76 Million |
0.071x | -70.91% |
| 2019-12-31 | CN¥399.83 Million ≈ $58.51 Million |
CN¥98.27 Million ≈ $14.38 Million |
0.246x | -17.16% |
| 2018-12-31 | CN¥301.83 Million ≈ $44.17 Million |
CN¥89.55 Million ≈ $13.10 Million |
0.297x | -0.72% |
| 2017-12-31 | CN¥281.09 Million ≈ $41.13 Million |
CN¥84.00 Million ≈ $12.29 Million |
0.299x | +77.64% |
| 2016-12-31 | CN¥194.57 Million ≈ $28.47 Million |
CN¥32.73 Million ≈ $4.79 Million |
0.168x | +229.95% |
| 2015-12-31 | CN¥52.67 Million ≈ $7.71 Million |
CN¥2.69 Million ≈ $392.95K |
0.051x | -- |
About Beijing Scitop Bio Tech Co Ltd
Beijing Scitop Bio-tech Co., Ltd. researches, develops, produces, and sells probiotic, postbiotics, and microecologival preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women's health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy … Read more